Affordable Access

deepdyve-link deepdyve-link
Publisher Website

The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial.

Authors
  • Kwon, Jung Hyun
  • Bae, Si Hyun
  • Lee, Youn Jae
  • Lee, Jin-Woo
  • Kim, Young Seok
  • Hwang, Jae Seok
  • Tak, Won Young
  • Jang, Jeong Won
  • Lee, Byung Seok
  • Lee, June Sung
  • Lee, Chun Kyon
  • Baik, Soon Koo
  • Park, Neung Hwa
  • Lee, Tae Hee
  • Kim, Dong Joon
  • Choi, Jae-Seok
  • Shin, Jae-Gook
  • Yim, Hyeon Woo
Type
Published Article
Journal
Hepatology international
Publication Date
Oct 01, 2013
Volume
7
Issue
4
Pages
1000–1009
Identifiers
DOI: 10.1007/s12072-013-9472-x
PMID: 26202029
Source
Medline
Keywords
License
Unknown

Abstract

In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (≥80 % of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.

Report this publication

Statistics

Seen <100 times